Navitas Reaches U.S. GaN Production Milestone, But Monetization Remains Unproven

What happened

Navitas announced delivery of its latest Gen 5 GaNFast chips manufactured in the U.S. via GlobalFoundries, a positive step that follows the partnership announced in November 2025 and aligns with management's plan for domestic production in late 2026. The master report had already flagged this as a medium-term catalyst, but it also emphasized that the company's revenue remains small, with Q2 2026 at $10.5 million and Q3 guidance around $13.5 million, far below its operating expense base. The report highlighted that Navitas has not yet disclosed booked AI production revenue, and management has repeatedly cautioned that design wins do not equal orders. While the manufacturing milestone reduces supply-chain risk and may improve qualification credibility, it does not address the core valuation gap: the stock at $11.4 already prices in AI data-center relevance that has not yet translated into auditable sales. The WAIT rating from the master report remains appropriate until the company demonstrates revenue conversion and resolves ongoing litigation risks.

Implication

The milestone reduces the risk of supply disruption and may improve qualification credibility with customers, aligning with the report's checklist that GlobalFoundries production start should align with named customer ramps. However, the fundamental picture remains weak: revenue is declining year-over-year, losses are substantial, and dilution has been heavy. The latest 10-Q disclosed two lawsuits that could disrupt products and timelines. The stock at $11.4 (as of July 27) already prices in AI data-center relevance, but the next 6-9 months will be critical: Q3 revenue must meet guidance and high-power mix improvement should continue; Q4 should show year-over-year growth; and management must disclose actual AI revenue. Without those, the stock is likely to remain range-bound or decline, and the WAIT rating is appropriate. Investors should monitor the October earnings report and any 8-K filings for evidence of production orders or revenue from the U.S. fab.

Thesis delta

The thesis has shifted marginally more positive because the company has achieved U.S. manufacturing production, which was a key technical milestone and reduces supply-chain risk. However, this does not alter the core bear-bull debate: the stock still trades on future AI revenue that has not yet been realized. The WAIT rating remains intact, as the news does not provide the auditable revenue proof required to justify current valuation.